Please login to the form below

Not currently logged in
Email:
Password:

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

Novartis

Novartis is to cut 1,700 jobs in Switzerland and around 400 jobs with the closure of its longstanding manufacturing facility in Grimsby, England.

The company announced the cuts today as part of a global programme first begun in 2016 to lower production costs and improve profitability.

Chief executive Vas Narasimhan says the cuts are part of Novartis’ strategy to move away from high-volume drug production towards more specialised and personalised medicines.

This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as Novartis’ CAR-T drug Kymriah.

The company is currently struggling to scale up its CAR-T production worldwide, and wants to divert more investment into the technology.

The company says it has already invested more than $1bn in new production technologies in Switzerland such as its Schweizerhalle facility in Basel, which includes a continuous production plant, cell and gene therapy production facilities, a device assembly building and a new launch facility.

In the UK, the company plans to close its Grimsby manufacturing site by 2020, affecting some 395 local employees.

Novarits’ UK country president Haseeb Ahmad said the decision was not linked to Brexit, and that "Novartis remains committed to the UK and believes that the UK is a world leader in life sciences".

The company says it will explore options for the site, including divestment, which could potentially allow the facility to stay open, and will consult closely and offer support to employees.

Article by
Andrew McConaghie

25th September 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...